ABSTRACT
Malaria still remains a life-threatening parasitic disease with universal targets set for control and elimination. This study aimed to evaluate the in vitro antimalarial susceptibility of Plasmodium falciparum isolates and Plasmodium berghei to selected antimalarial agents and column chromatographic subfractions of Glyphaea brevis leaves extract and FTIR and GCMS of SF8. Trager and Jensen as well as World Health Organisation (WHO) standardised in vitro micro-test system methods were used to determine susceptibility on the patients' blood samples; Column chromatographic procedure was carried out to obtain 11 pooled fractions; FTIR and GCMS were used to determine functional groups and phytochemicals respectively. In vitro anti-plasmodial activity against P. falciparum clinical isolates had IC50 range of 1.03 µg/mL-7.63 µg/mL while their IC50 against P. berghei ranges from 4.32 µg/mL-7.89 µg/mL. Subfraction 8 (SF8) had the least IC50 of 4.32 µg/mL. The FTIR spectrum showed the presence of isoprenoid, alcohol, phenol, alkane, alkenes, ester, carboxylic acids, aromatics and nitro compounds while GCMS identified dodecanoic acid, methyl ester; carotol; hexadecanoic acid, methyl ester; 9-octadecenoic acid (Z)-, methyl ester (oleic acid); methyl stearate; heptadecanoic acid, 16-methyl-, methyl ester; all with their antimalarial reported activities. In conclusion, G. brevis has a great potential for drug development against malaria parasite since it inhibited schizont growth and possesses phytocompounds with antimalarial report.
ABSTRACT
Oxidative stress and inflammation have been proven to be implicated in the pathogenesis of type 2 diabetes. Recent studies showed that Ethulia conyzoides had in-vitro antioxidant activity. This study investigated the in-vivo antidiabetic, antioxidant, and anti-inflammatory potential of the residual aqueous fraction of Ethulia conyzoides in type 2 diabetic-induced male Wistar rats. Sub-acute antidiabetic studies were done with varying doses (100, 200, and 400 mg/kg body weight) of residual aqueous fraction for 21 days. Blood glucose levels, serum insulin, and in vivo antioxidant and pro-inflammatory cytokines-tumour necrosis factor-α (TNF-α) and interleukin-1ß (IL-1ß) -were measured at the end of the treatment. When rats were given different concentrations of residual aqueous fraction, there was a significant (p < 0.05) reduction in blood glucose, malondialdehyde (MDA), IL-1ß, and TNF-α levels, as well as a significant (p < 0.05) increase in SOD (superoxide dismutase), catalase and insulin levels when compared to the diabetic control group. Furthermore, the 400 mg/kg body weight dosage concentration was found to be the most effective. This result suggests that the residual aqueous fraction of Ethulia conyzoides possesses significant antidiabetic, antioxidant and anti-inflammatory activities.
